Nuclear Medicine Market to Reach USD 55.75 Billion by 2034; Increasing Usage of Theranostics and Clinical Success for Radioligand to Elevate Market Growth

The global nuclear medicine market size was valued at USD 11.77 billion in 2025 and is estimated to reach USD 13.72 billion in 2026. By exhibiting a CAGR of 19.15% over the forecast period, the market is set to hit USD 55.75 billion by 2034. Fortune Business Insights™ presents this information in its report titled “Nuclear Medicine Market Size, Share & Industry Analysis, By Type (Diagnostics {PET Radiopharmaceuticals [FDG-PET/18F, 68Ga, 68Cu, 11C, and Others], and SPECT Radiopharmaceuticals [Technetium-99m, Iodine-123, Xenon-133, Thallium-201, and Others]}, and Therapeutics {Ra-223, Sm-153, Lu-177, I-131, Y-90, and Others}), By Application (Neurology, Cardiology, Oncology, and Others), By End-user (Hospitals & Clinics, Diagnostic Centers, and Others), and Regional Forecast, 2026-2034”.

Prevalence of neurological diseases, cancer, and cardiac disorders; development in radioisotope supply, imaging infrastructure, and theranostics, and investments in isotope production and commercial distribution form the backbone of market development. Clinical use of nuclear medicine in specialty centers and hospitals has increased its demand globally.

The nuclear medicine market has gained momentum due to rising use of theranostics – a single clinical pathway combining targeted therapy and diagnostic imaging. To illustrate, GE HealthCare’s latest theranostics-focused technology integrates radiopharmaceuticals, AI-powered software, and cutting-edge diagnostic imaging for precision oncology care.

Curium’s First Dosimetry and Pharmacokinetics Data Focuses on Evaluating Lu-177 Zadavotide Guraxetan

Curium announced the first dosimetry and pharmacokinetics (PK) data in February 2026 from a substudy of the pivotal Phase 3 ECLIPSE clinical trial (NCT05204927). It evaluates lutetium-177 (Lu-177) zadavotide guraxetan, an investigational PSMA-targeted radioligand therapy, for patients with mCRPC progressing on prior ARPI. The nonrandomized PK/dosimetry substudy was conducted as part of the ECLIPSE trial. It focused on evaluating the biodistribution and absorbed radiation dose of Lu-177 zadavotide guraxetan in organs of interest.

Clinical Success for Radioligand will Push Nuclear Medicine Industry to New Heights

Radiopharmaceuticals usage delivers enhanced treatment precision as they limit damage to healthy tissue while directing radiation to diseased cells. Increased confidence among healthcare systems and physicians due to clinical success in radioligand improves adoption in oncology settings. A case in point, Novartis’ Pluvicto received U.S. FDA approval in March 2025 and can be used in patients with PSMA, prior to opting out for chemotherapy.

However, scarcity of trained professionals and limited reimbursement for diagnostic radiopharmaceuticals may discourage the nuclear medicine market growth.

Industry Giants Maintain Strong Position with Market Expansion Plans

The global market for nuclear medicine depicts a semi-fragmented structure. Bracco, Bayer AG, Novartis AG, Sotera Health, Siemens Healthineers AG, and Curium are few big names holding substantial market share. Market expansion strategies such as pipeline development, strong capital inflow, novel product introductions, and partnerships also assist in gaining robust revenue. Lantheus Holdings, Inc., a dominant player in the market, received U.S. FDA approval for its Lutetium Lu 177 Dotatate (PNT 20023) in March 2026.

Key Industry Development

• March 2026: Perspective Therapeutics’ VMT-α-NET data was accepted for presentation at AACR 2026. This move fortifies momentum behind targeted alpha therapy in neuroendocrine tumors.

List of Key Players Profiled in the Report

• GE HealthCare (U.S.)
• Lantheus Holdings, Inc. (U.S.)
• Nordion (Canada) Inc. (Sotera Health) (Canada)
• Bracco (Italy)
• Curium (France)
• Bayer AG (Germany)
• Siemens Healthineers AG (Germany)
• Novartis AG (Switzerland)
• Jubilant Pharmova Limited (India)
• Cardinal Health (U.S.)
• Norgine (U.K.)
• DuchemBio, Co., Ltd. (South Korea)

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/nuclear-medicine-radiopharmaceuticals-market-101812

Further Report Findings

• North America garnered a dominant revenue of USD 6.20 billion in 2025 on the back of its cutting edge imaging infrastructure, capital allocation for radiopharmaceutical manufacturing, and increased uptake of PET and SPECT procedures.
• Europe’s strong growth rate of 17.59% is set to achieve progress over the forecast period via radiopharmaceutical ecosystem, research activities, and targeted cancer diagnosis and therapy.
• Oncology holds a monopoly in nuclear medicine market share by application on the back of investments in oncology-focused radiopharmaceutical pipelines and isotope supply.

Table of Segmentation